Changes to the statin prescribing policy in Belgium: Potential impact in clinical and economic terms

American Journal of Cardiovascular Drugs

Volumn 12, Issue 4, 2012, Pages 225-232

  Liew, Danny ^a   Webb, Kate ^a   Marbaix, Sophie ^b   Annemans, Lieven ^c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b PFIZER INC   (United States)

^c GHENT UNIVERSITY   (Belgium)

Author keywords

cardiovascular diseases; cost effectiveness analysis.; drug switching; health policy; HMG CoA reductase inhibitors

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; SIMVASTATIN;

ADULT; AGED; ARTICLE; BELGIUM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DEATH; DECISION MAKING; DRUG COST; FEMALE; HEALTH CARE POLICY; HEALTH ECONOMICS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS;

AGED; BELGIUM; CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; DRUG AND NARCOTIC CONTROL; DRUG COSTS; DRUG UTILIZATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; MALE; MARKOV CHAINS; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS;

EID: 84863914312     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.1007/bf03261831     Document Type: Article

References (32)

1. Agreement initially published in Belgian Official Journal on 2009 January 19 [online]. Available from URL: http://www.inami.fgov.be/care/fr/doctors/ general-information/agreements/2009-2010/index.htm (In French and Dutch) [Accessed 2011 Jun 10]
2. Recommendation initially published in Belgian Official Journal on 2010 August 20 [online]. Available from URL: http://www.inami.fgov.be/drug/fr/ drugs/recommendation/pdf/brochure.pdf (In French and Dutch) [Accessed 2011 Jun 10]
3. Stichting Farmaceutische Kengetallen. Beoogde besparing op statines onzeker. Pharmaceutisch Weekblad 2009; 144 [online]. Available from URL: http:// www.sfk.nl/ [Accessed 2011 May 4]
4. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003; 326: 1423-7
5. Rogers SL, Magliano DJ, Levison DB, et al. A dose-specific meta-analysis of lipid changes in randomized controlled trials of atorvastatin and simvastatin. Clin Ther 2007; 29: 242-52
6. Hess G, Sanders KN, Hill J, et al. Therapeutic dose assessment of patient switching from atorvastatin to simvastatin.AmJ Manag Care 2007; 13 Suppl. 3: S80-5
7. Phillips B, Roberts C, Rudolph AE, et al. Switching statins: the impact on patient outcomes. Br J Cardiol 2007; 14: 280-5
8. Chapman RH, Benner JS, Girase P, et al. Generic and therapeutic statin switches and disruptions in therapy. Curr Med Res Opin 2009; 25: 1247-60
9. Colivicchi F, Tubaro M, Santini M. Clinical implications of switching from intensive to moderate statin therapy after acute coronary syndromes. Int J Cardiol 2011; 152: 56-60
10. Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 1998; 13: 397-409
11. Lilford RJ, Pauker SG, Braunholtz DA, et al. Decision analysis and the implementation of research findings. BMJ 1998; 317: 405-9
12. Svilaas A, McGrath C, van Campenhout H, et al. A descriptive study of cardiovascular risk management and statin therapy in Belgian and Norwegian general practice. Int J Primary Health Care 2012. In press
13. Anderson KM, Odell PM, Wilson PWF, et al. Cardiovascular risk profiles.Am Heart J 1990; 121: 293-8
14. De Bacquer D, De Backer G. The prevalence of concomitant hypertension and hypercholesterolaemia in the general population. Int J Cardiol 2006; 110: 217-23
15. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987-1003
16. Graham I, Atar D, Borch-Johnsen K, et al., for the Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 2007; 28: 2375-414
17. Steg PG, Bhatt DL, Wilson PWF, et al., for the REACH Registry Investigators. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 2007; 297:1197-206
18. Statistiek van de doodsoorzaken [online]. Available from URL: http://www. zorg-en-gezondheid.be/cijfers/sterftecijfers/statistiek-van-de-doodoorzaken (In Dutch) [Accessed 2010 Oct 10]
19. Greving JP, Buskens E, Koffijberg H, et al. Cost-effectiveness of aspirintreatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk. Circulation 2008; 117: 2875-83
20. Annemans L, Lamotte M, Levy E, et al. Cost-effectiveness analysis of clopidogrel versus aspirin in patients with atherothrombosis based on the CAPRIE trial. J Drug Assessment 2003; 6: 107-20
21. Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006; 295: 180-9
22. Lamotte M, Annemans L, Kawalec P, et al. A multi-country health economic evaluation of highly concentrated N-3 polyunsaturated fatty acids in secondary prevention after myocardial infarction. Pharmacoeconomics 2006; 24: 783-95
23. Royal Decree of 21 December 2001 modified on 26 January 2011, published in the Belgian Official Journal [online]. Available from URL: http://www.inami. be/drug/fr/drugs/reglementation/legal-texts/ar-20011221/index.htm [Accessed 2011 Jun 10]
24. Cleemput I, Van Wilder P, Vrijens F, et al. KCE report 78. Recommendations pour les évaluations pharmaco-économiques en Belgique (in French) [online]. Available from URL: http://www.kce.fgov.be/index- fr.aspx?SGREF=3465 &CREF=11008 [Accessed 2011 Jun 10]
25. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000; 17 (5): 479-500
26. Thiebaud P, Patel BV, Nichol MB, et al. The effect of switching on compliance and persistence: the case of statin treatment.AmJ Manag Care 2005; 11: 670-4
27. Weinstein MC. Recent developments in decision-analytic modeling for economic evaluation. Pharmacoeconomics 2006; 24: 1043-53
28. Unites States Food and Drug Administration. FDA Drug Safety Communication: new restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury [online]. Available from URL: http://www.fda.gov/Drugs/DrugSafety/ucm256581.htm#sa [Accessed 2012 Feb 14]
29. Bestehorn K, Greiner W. Effects of the introduction of fixed prices for statins on lipid levels in Germany. J Public Health 2008; 16: 215-9
30. Rublee DA, Burke JP. LDL-C goal attainment in patients who remain on atorvastatin or switch to equivalent or non-equivalent doses of simvastatin: a retrospectivematched cohort study in clinical practice. Postgrad Med 2010; 122: 16-24
31. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterollowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-78
32. Aronow HD, Hess G, Hill J, et al. Switching from atorvastatin to simvastatin in patients at high cardiovascular risk: effects on low-density lipoprotein cholesterol. Am J Ther 2010; 17: 167-75